浙江维康药业股份有限公司 未来三年（2025-2027 年）股东回报规划 为了完善和健全公司科学、持续、稳定的股东回报机制，增加利润分配决策 的透明度和可操作性，切实保护公众投资者合法权益，根据中国证监会《上市公 司监管指引第 3 号——上市公司现金分红》等有关法律、法规以及《公司章程》 的有关规定，浙江维康药业股份有限公司（以下简称"公司"）结合实际情况， 特制定公司未来三年（2025-2027 年）股东回报规划（以下简称"本规划"）。 公司着眼于平稳、健康和可持续发展，在综合分析公司经营发展现状、股东 意愿、发展目标、社会资金成本和外部融资环境等因素的基础上，充分考虑公司 目前及未来盈利规模、现金流量状况、发展所处阶段、项目投资资金需求、银行 信贷及债权融资环境等情况，建立对投资者持续、稳定、科学的回报机制，对公 司利润分配做出明确的制度性安排，保持利润分配政策的连续性和稳定性。 二、本规划的制定原则 本规划将在符合国家相关法律法规及《公司章程》的前提下，充分重视对投 资者的回报，保持公司的利润分配政策的连续性和稳定性，同时兼顾公司的长远 利益、全体股东的整体利益及公司的可持续发展。公司在利润分配政策的研 ...

浙江维康药业股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开 了第四届董事会第五次会议，会议审议通过了《关于提请召开公司 2024 年度股东 大会的议案》，同意于 2025 年 5 月 20 日召开公司 2024 年度股东大会。现将本 次股东大会的相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会 2、会议召集人：公司董事会。 证券代码：300878 证券简称：维康药业 公告编号：2025-020 3、会议召开的合法性、合规性：公司第四届董事会第五次会议审议通过了《关 于提请召开公司 2024 年度股东大会的议案》。本次股东大会的召集、召开所履行 的程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》等的有 关规定。 4、会议召开日期和时间： （1）现场会议召开：2025 年 5 月 20 日（星期二）下午 14:00。 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-009 浙江维康药业股份有限公司 第四次监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日以电 子邮件、专人送达或电话方式发出第四次监事会第五次会议通知，会议于 2025 年 4 月 27 日在浙江省丽水经济开发区遂松路 2 号研发大楼二楼会议室以现场方 式召开，应参加表决的监事 3 人，实际参加表决的监事 3 人，会议由公司监事会 主席叶志学主持。本次会议的召集、召开和表决程序符合有关法律、法规、部门 规章、规范性文件和《公司章程》的规定，会议形成的决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于公司 2024 年度监事会工作报告的议案》 公司监事会审议通过了《2024 年度监事会工作报告》，具体内容详见公司 同日在巨潮资讯网（http://www.cninfo.com.cn）披露的《公司 2024 年度监事会工 作报告》。 表决结果：3 票同意，0 票反对， ...

证券代码：300878 证券简称：维康药业 公告编号：2025-008 二、董事会会议审议情况 （一）审议通过《关于公司 2024 年度总经理工作报告的议案》 与会董事认真听取了总经理刘洋先生所作的《2024 年度总经理工作报告》， 董事会认为 2024 年度公司经营管理层有效地执行了董事会和股东大会的各项决 议，该报告客观、真实地反映了经营管理层 2024 年度的主要工作。 表决结果：同意：7 票；反对：0 票；弃权：0 票。 （二）审议通过《关于公司 2024 年度董事会工作报告的议案》 浙江维康药业股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）第四届董事会第五次会议 通知于 2025 年 4 月 17 日以电子邮件、专人送达或电话方式送达全体董事，本次 会议于 2025 年 4 月 27 日在浙江省丽水经济开发区遂松路 2 号二楼会议室以现场 结合通讯方式召开。本次会议由董事长刘洋先生主持，公司应出席董事 7 人，实 际出席董事 7 人。本 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-016 | 项 目 | 调整前金额 | 调整金额 | 调整后金额 | | --- | --- | --- | --- | | 其他应收款 | 11,554,269.55 | 17,544,475.55 | 29,098,745.10 | | 其他流动资产 | 23,927,015.34 | -564,510.96 | 23,362,504.38 | | 固定资产 | 529,833,584.44 | 29,610,251.59 | 559,443,836.03 | | 在建工程 | 301,907,569.27 | -31,475,373.90 | 270,432,195.37 | | 资产总计 | 2,046,636,530.88 | 15,114,842.28 | 2,061,751,373.16 | | 应交税费 | 5,437,966.56 | 14,321,505.02 | 19,759,471.58 | | 负债合计 | 639,227,731.24 | 14,321,505.02 | 653,549,236.26 | | 盈余公积 ...

Financial Performance - The company reported a significant decline in performance, primarily due to the transfer of its wholly-owned subsidiaries, resulting in a non-recurring investment income of RMB 88.25 million, while also recognizing fixed asset impairment of RMB 76.20 million[3]. - Product sales revenue and gross margin decreased due to a drop in product prices and underperformance in sales and management[4]. - The company's operating revenue for 2024 was ¥351,198,567.67, a decrease of 32.41% compared to ¥519,621,071.15 in 2023[21]. - The net loss attributable to shareholders for 2024 was ¥-147,426,253.43, representing a significant increase of 1,546.42% from a loss of ¥-8,038,557.83 in 2023[21]. - The net cash flow from operating activities for 2024 was ¥-27,173,007.35, a decline of 146.62% from ¥58,289,136.41 in 2023[21]. - The total assets at the end of 2024 were ¥1,652,323,039.5, down 19.86% from ¥2,046,636,530.88 at the end of 2023[21]. - The net assets attributable to shareholders decreased by 16.75% to ¥1,157,666,559.7 at the end of 2024 from ¥1,389,807,852.57 at the end of 2023[21]. - The company reported a basic and diluted earnings per share of ¥-1.03 for 2024, a decrease of 1,616.67% from ¥-0.06 in 2023[21]. - The weighted average return on equity for 2024 was -11.75%, compared to -0.58% in 2023[21]. - The company reported a net profit attributable to shareholders of -¥191,521,798.32 in Q4, highlighting substantial losses in the last quarter[28]. Investment and R&D - The company plans to enhance its profitability by advancing core R&D projects, including innovative traditional Chinese medicine products and improved formulations, with a focus on market-ready short-term projects[6]. - The company emphasizes R&D investment and talent acquisition, establishing multiple research platforms to enhance its core competitiveness in the pharmaceutical field[40]. - The company is currently advancing several key projects, including the "Bone Spur Capsule," which is under review by the National Pharmacopoeia Committee[52]. - The "Yinhuang Diban" is in the clinical trial phase, having completed Phase II trials and currently in communication for Phase III trials[52]. - The company is conducting research on multiple traditional Chinese medicine formulations, including "Jichuan Decoction" and "Wenjing Decoction," which are in various stages of development[52]. - The company holds 37 drug approval numbers, with key products like Yinhuang Diban and Luohongmycin Soft Capsules having invention patents and core technologies[56]. - The company has established multiple research platforms, including provincial high-tech enterprise R&D centers and has received various provincial science and technology awards[56]. - The company plans to submit applications for several new traditional Chinese medicine products, enhancing its product line and potential revenue streams[80]. Market Strategy and Expansion - Efforts will be made to include more core products in the national medical insurance directory, which is expected to boost demand and market expansion[7]. - The company aims to increase production capacity for existing products and new product commercialization through investments in modern facilities[7]. - A nationwide marketing network has been established, with plans to further enhance its coverage and the professionalism of the sales team to support sustainable growth[7]. - The company is currently enhancing its research plans based on prior communications with CDE regarding the Silver Yellow Inhalation Solution[56]. - The company aims to strengthen the development of traditional Chinese medicine in response to national policies promoting healthcare and innovation in the pharmaceutical industry[36]. - The company is focused on maintaining the rights and interests of all shareholders through diligent oversight[166]. - The company plans to continue expanding its market presence and product development in the pharmaceutical sector[98]. Human Resources and Management - The company will strengthen human resource management and talent acquisition to support its rapid development and maintain a stable workforce[9]. - The management team has extensive experience in the pharmaceutical industry, contributing to effective market development and product quality control[60]. - The company has established an independent human resources department with a complete personnel management system[134]. - The company has a well-structured internal management organization, including a shareholders' meeting, board of directors, and supervisory board, ensuring independent operational authority[136]. - The company has a total of 650 employees, including 232 production personnel, 252 sales personnel, 87 technical personnel, 22 financial personnel, and 57 administrative personnel[172]. - The company emphasizes talent cultivation and has developed a comprehensive training system to enhance employee skills and meet the company's development needs[175]. Financial Management and Compliance - The company corrected prior financial statements due to a misappropriation of funds totaling ¥157,300,000, which included ¥54,000,500 of raised funds[22]. - The company plans to continue monitoring the use of raised funds and has transferred ¥54,000,500 back to the designated account[22]. - The company has a well-developed new drug research and development system, emphasizing market research and strict control at all stages, while increasing investment in R&D and talent acquisition to mitigate product development risks[117]. - The company has established a comprehensive quality management system based on drug quality risk assessment to ensure compliance with safety, efficacy, and quality control requirements throughout the production process[116]. - The company is actively monitoring changes in national pharmaceutical policies to proactively develop response measures[113]. - The company has been under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[184]. - The company emphasizes compliance with laws and regulations, ensuring accurate and timely information disclosure to enhance operational transparency[188]. Shareholder and Governance - The board approved a profit distribution plan, proposing a cash dividend of RMB 1.4 per 10 shares, with no bonus shares issued[9]. - The company announced a change in leadership with Liu Yang being elected as Chairman and General Manager effective May 20, 2024[142]. - The company has a complete governance structure with independent directors and a supervisory board[141]. - The company has committed to not engage in direct or indirect competition with its own subsidiaries to protect its interests[194]. - The company will avoid similar investment projects to prevent competition with its own interests[194]. - The company has a strategy in place to address any potential misleading information in its public offering documents[200]. - The company is committed to establishing an investor compensation fund to address potential losses[200]. Operational Challenges - The company is facing challenges due to declining product prices and management performance, leading to adjustments in production plans[72]. - The company has reported a total of 5.5 million yuan in unused raised funds that have been idle for over two years[95]. - The investment in the pharmaceutical health industry park project has not met expected returns primarily due to lower-than-expected sales during the period[98]. - The company is currently advancing core R&D projects, including innovative traditional Chinese medicine products, with significant investment in research and development[105]. - The company faces policy risks related to the ongoing reforms in the medical and pharmaceutical sectors, which may impact its operations if not addressed timely[112].

Financial Performance - The company's revenue for Q1 2025 was ¥69,775,938.28, a decrease of 65.10% compared to ¥199,953,044.93 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥9,854,658.34, representing a decline of 140.50% from a profit of ¥24,334,978.24 in the previous year[5] - The basic earnings per share for the period was -¥0.07, down 141.18% from ¥0.17 in the same period last year[5] - Net profit for the period was a loss of ¥9,706,327.17 compared to a profit of ¥24,389,323.96 in the previous period, indicating a significant downturn[18] - The company's net profit margin and future guidance were not explicitly detailed in the provided documents[12] Cash Flow and Operating Activities - The net cash flow from operating activities improved to -¥6,488,555.71, a 60.53% increase compared to -¥16,439,476.59 in the same period last year[5] - Operating cash flow net amount was a negative ¥6,488,555.71, an improvement from a negative ¥16,439,476.59 in the previous period[21] - Cash and cash equivalents at the end of the period increased to ¥259,807,484.08 from ¥225,921,021.74, showing a positive change[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,638,649,780.40, a decrease of 0.83% from ¥1,652,323,039.56 at the end of the previous year[5] - The total assets of Zhejiang Weikang Pharmaceutical Co., Ltd. as of March 31, 2025, amounted to CNY 1,638,649,780.40, a decrease from CNY 1,652,323,039.56 at the beginning of the period[14] - Total current liabilities decreased to CNY 228,091,892.00 from CNY 240,381,545.98, a reduction of about 5.1%[15] - Long-term borrowings increased to CNY 197,372,877.74 from CNY 186,619,205.86, reflecting an increase of approximately 5.7%[15] - The total equity attributable to the parent company decreased to CNY 1,147,811,901.37 from CNY 1,157,666,559.71, a decline of about 0.9%[16] Sales and Expenses - The cash received from sales of goods and services was ¥58,473,216.71, a decrease of 54.16% from ¥127,565,675.80 in the previous year[9] - Total operating revenue decreased to ¥69,775,938.28 from ¥199,953,044.93, representing a decline of approximately 65% year-over-year[17] - Total operating costs decreased to ¥79,431,824.89 from ¥173,888,443.65, a reduction of about 54% year-over-year[17] - The company reported a decrease in sales expenses to ¥30,418,191.53 from ¥52,336,889.43, a reduction of approximately 42% year-over-year[17] - Research and development expenses slightly decreased to ¥2,671,042.00 from ¥2,971,220.93, a decline of about 10% year-over-year[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,248, with the largest shareholder holding 60.89% of the shares[10] Asset Impairment and Credit Quality - The company reported a significant increase in asset impairment losses, which rose by 4354.98% to ¥1,541,958.53 compared to -¥34,612.01 in the previous year[9] - The company incurred a credit impairment loss of ¥4,867,447.87 compared to a gain of ¥4,978,010.08 in the previous period, indicating a significant shift in credit quality[18] Government Support and Investments - The company received government subsidies amounting to ¥2,060,338.52 during the reporting period[6] - The total cash inflow from investment activities was ¥44,625,315.68, a decrease from ¥250,969,467.74 in the previous period[21] Market and Product Development - There were no significant updates on new product developments or market expansions mentioned in the conference call[12] - The company did not report any mergers or acquisitions during this period[12]

| 投资主体 | 受托方 | 关联 | 产品名称 | 产品类型 | 委托理 财金额 | 起始日期 | | 到期日期 | 预期年化 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | | | （万元） | | | | 收益率 | | 浙江维康 药业股份 | 东亚前海 证券有限 | 无 | 东亚前海证券 | 固定收益 | 500 | | | 按周赎回 每周一、 | 最终收益 以实际支 | | | | | 祥裕周周享 1 | 类集合资 | | 2025 4 | 年 | | | | | | | 号集合资产管 | 产管理计 | | 月 1 | 日 | | | | 有限公司 | 责任公司 | | | | | | | 周三 | 付为准 | | | | | 理计划 | 划 | | | | | | 一、理财产品的基本情况 二、审批程序 公司第四届董事会第四次会议、第四届监事会第四次会议，审议通过了《关 于使用闲置自有资金进行委托理财的议案》，本次购买理财产品的额度和期限均 在审批范围内，无需另行提交董事会或者股东大会审议。 证券代 ...

Group 1: Company Performance - Western Gold achieved operating revenue of 7.001 billion yuan in 2024, a year-on-year increase of 56.68%, and net profit of 290 million yuan, turning from loss to profit [1] - Jihong Co. reported operating revenue of 5.529 billion yuan in 2024, a year-on-year decrease of 17.41%, with net profit down 47.28% to 182 million yuan [2] - Sanli Co. achieved operating revenue of 227 million yuan in 2024, a year-on-year increase of 14.35%, but reported a net loss of 49.88 million yuan, narrowing the loss by 56.50% [2] - Sanli Co. reported operating revenue of 2.590 billion yuan in 2024, a year-on-year increase of 25.25%, with net profit of 68.09 million yuan, up 59.07% [4] - Huaiqi Mountain achieved operating revenue of 1.631 billion yuan in 2024, a year-on-year increase of 15.60%, with net profit of 196 million yuan, up 17.74% [6] - Huayuan Holdings reported operating revenue of 2.449 billion yuan in 2024, a year-on-year increase of 1.60%, with net profit of 70.74 million yuan, up 739% [8] - Hangfa Power achieved operating revenue of 47.880 billion yuan in 2024, a year-on-year increase of 9.48%, but net profit decreased by 39.48% to 860 million yuan [10] - Zhongcai Energy reported operating revenue of 2.324 billion yuan in 2024, a year-on-year decrease of 24.21%, with net profit down 94.70% to 760,240 yuan [10] - Longxing Technology achieved operating revenue of 4.355 billion yuan in 2024, a year-on-year increase of 1.95%, with net profit of 142 million yuan, up 28.70% [11] - Jinying Co. reported operating revenue of 1.308 billion yuan in 2024, a year-on-year decrease of 4.52%, with net profit down 36.73% to 22.35 million yuan [12] - Zhujiang Co. achieved operating revenue of 1.558 billion yuan in 2024, a year-on-year decrease of 52.38%, but net profit turned to profit at 15.57 million yuan [12] - Chuanwang Media reported operating revenue of 288 million yuan in 2024, a year-on-year increase of 20.05%, but net profit decreased by 24.02% to 23.80 million yuan [13] - Ronglian Technology achieved operating revenue of 2.022 billion yuan in 2024, a year-on-year decrease of 14.91%, with net profit of 28.11 million yuan, up 107.87% [13] - Oufeiguang reported operating revenue of 20.437 billion yuan in 2024, a year-on-year increase of 21.19%, but net profit decreased by 24.09% to 58.38 million yuan [14] Group 2: Dividend Proposals - Western Gold proposed a cash dividend of 0.5 yuan per 10 shares [1] - Jihong Co. proposed a cash dividend of 1.58 yuan per 10 shares [2] - Sanli Co. proposed a cash dividend of 1.50 yuan per 10 shares [4] - Huaiqi Mountain proposed a cash dividend of 4.00 yuan per 10 shares [6] - Huayuan Holdings proposed a cash dividend of 1.00 yuan per 10 shares [8] - Hangfa Power proposed a cash dividend of 0.97 yuan per 10 shares [10] - Zhongcai Energy proposed a cash dividend of 0.05 yuan per 10 shares [10] - Longxing Technology proposed a cash dividend of 1.20 yuan per 10 shares [11] - Jinying Co. proposed a cash dividend of 1.00 yuan per 10 shares [12] - Zhujiang Co. proposed a cash dividend of 1.25 yuan per 10 shares [12] - Chuanwang Media proposed a cash dividend of 1.25 yuan per 10 shares [13] - Ronglian Technology proposed a cash dividend of 0.0425 yuan per share [13] - Oufeiguang proposed a cash dividend of 0.0178 yuan per share [14]

证券代码：300878 证券简称：维康药业 公告编号：2025-005 浙江维康药业股份有限公司 关于获得二冬汤颗粒上市申请受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于近日获得国家药品监督 管理局发出的二冬汤颗粒药品注册上市许可申请《受理通知书》。现将相关情况 公告如下： 一、受理通知书主要内容 产品名称：二冬汤颗粒 申请事项：境内生产药品注册上市许可 特此公告。 申请人：浙江维康药业股份有限公司 受理号：CXZS2500013 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以 受理。 二、二冬汤颗粒的相关情况 二冬汤颗粒，润肺清胃。主治上消。症见烦渴不止，小便频数，脉数无力等。 三、同类药品的情况 截至本公告披露日，经查询国家药品监督管理局网站，取得该品种的药品批 准文号的企业有：江西药都樟树制药有限公司、贵州威门药业股份有限公司。 四、对公司的影响及风险提示 根据国家相关法规规定，上述药品已获得注册申请受理，报送国家药监局药 品审评中心进行审评审批。上述药品获得受理通知书 ...